FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379332249> ?p ?o ?g. }

• W4379332249 endingPage "e16586" @default.
• W4379332249 startingPage "e16586" @default.
• W4379332249 abstract "e16586 Background: Immune checkpoint inhibitor (ICI) therapy is a novel and promising agent for treating muscle invasive bladder cancer (MIBC). However, there is a need for further understanding of which patient factors or biological markers can be used to help identify patients who will have a successful response to ICI therapy. We hypothesized that Neutrophil-to-Lymphocyte Ratio (NLR) could be predictive of response to ICI therapy as this ratio has previously been reported to correlate with a higher number of myeloid derived suppressor cells. Methods: A retrospective cohort analysis was performed on patients with advanced or metastatic bladder cancer who were treated with ICI therapy at a single institution between 2015-2020. Information on survival, disease recurrence, and patient characteristics was gathered. Neutrophil and lymphocyte numbers were recorded at time of ICI administration and a ratio of neutrophils to lymphocytes was calculated. The median of these values was calculated and used to divide the cohort into low NLR and high NLR. Tissue samples from a subset of these patients were collected and sent for multiplex immunohistochemistry with a myeloid and T cell staining panel. Results: In a cohort of 115 patients with advanced bladder cancer treated with ICI, the mean time to last follow up or event (death or disease progression) was 375.78 days (SD 41). 35 patients (30%) had either a complete or partial response to ICI therapy. A Kaplan Meier survival analysis shows a significant difference in survival between the low and high NLR group, with lower NLR having a longer event free survival (Wilcoxon rank p = 0.0156). Multiplex IHC showed variable tumor and adjacent microenvironmental distributions of myeloid and lymphoid marker positive populations in ICI responders and non-responders. Conclusions: In an effort to better predict which patients may benefit from ICI therapy, we have studied NLR at the time of ICI administration and its association with event free survival. Our results suggest that a lower NLR could be associated with a longer event free survival. Further research is being conducted to study the immune microenvironment as it relates to bladder cancer response to ICI therapy." @default.
• W4379332249 created "2023-06-05" @default.
• W4379332249 creator A5004894140 @default.
• W4379332249 creator A5015241404 @default.
• W4379332249 creator A5022753685 @default.
• W4379332249 creator A5024482335 @default.
• W4379332249 creator A5031016267 @default.
• W4379332249 creator A5034605162 @default.
• W4379332249 creator A5042184224 @default.
• W4379332249 creator A5054444820 @default.
• W4379332249 creator A5054519252 @default.
• W4379332249 creator A5060948890 @default.
• W4379332249 creator A5070610462 @default.
• W4379332249 creator A5072435293 @default.
• W4379332249 creator A5072481226 @default.
• W4379332249 creator A5073148665 @default.
• W4379332249 creator A5078447958 @default.
• W4379332249 creator A5085980531 @default.
• W4379332249 creator A5090337234 @default.
• W4379332249 creator A5091808340 @default.
• W4379332249 date "2023-06-01" @default.
• W4379332249 modified "2023-10-06" @default.
• W4379332249 title "Neutrophil-to-lymphocyte ratio as a predictor of immune checkpoint inhibitor therapy response in advanced bladder cancer." @default.
• W4379332249 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e16586" @default.
• W4379332249 hasPublicationYear "2023" @default.
• W4379332249 type Work @default.
• W4379332249 citedByCount "0" @default.
• W4379332249 crossrefType "journal-article" @default.
• W4379332249 hasAuthorship W4379332249A5004894140 @default.
• W4379332249 hasAuthorship W4379332249A5015241404 @default.
• W4379332249 hasAuthorship W4379332249A5022753685 @default.
• W4379332249 hasAuthorship W4379332249A5024482335 @default.
• W4379332249 hasAuthorship W4379332249A5031016267 @default.
• W4379332249 hasAuthorship W4379332249A5034605162 @default.
• W4379332249 hasAuthorship W4379332249A5042184224 @default.
• W4379332249 hasAuthorship W4379332249A5054444820 @default.
• W4379332249 hasAuthorship W4379332249A5054519252 @default.
• W4379332249 hasAuthorship W4379332249A5060948890 @default.
• W4379332249 hasAuthorship W4379332249A5070610462 @default.
• W4379332249 hasAuthorship W4379332249A5072435293 @default.
• W4379332249 hasAuthorship W4379332249A5072481226 @default.
• W4379332249 hasAuthorship W4379332249A5073148665 @default.
• W4379332249 hasAuthorship W4379332249A5078447958 @default.
• W4379332249 hasAuthorship W4379332249A5085980531 @default.
• W4379332249 hasAuthorship W4379332249A5090337234 @default.
• W4379332249 hasAuthorship W4379332249A5091808340 @default.
• W4379332249 hasConcept C121608353 @default.
• W4379332249 hasConcept C126322002 @default.
• W4379332249 hasConcept C143998085 @default.
• W4379332249 hasConcept C203014093 @default.
• W4379332249 hasConcept C2777761686 @default.
• W4379332249 hasConcept C2779282312 @default.
• W4379332249 hasConcept C2780352672 @default.
• W4379332249 hasConcept C71924100 @default.
• W4379332249 hasConcept C72563966 @default.
• W4379332249 hasConcept C90924648 @default.
• W4379332249 hasConceptScore W4379332249C121608353 @default.
• W4379332249 hasConceptScore W4379332249C126322002 @default.
• W4379332249 hasConceptScore W4379332249C143998085 @default.
• W4379332249 hasConceptScore W4379332249C203014093 @default.
• W4379332249 hasConceptScore W4379332249C2777761686 @default.
• W4379332249 hasConceptScore W4379332249C2779282312 @default.
• W4379332249 hasConceptScore W4379332249C2780352672 @default.
• W4379332249 hasConceptScore W4379332249C71924100 @default.
• W4379332249 hasConceptScore W4379332249C72563966 @default.
• W4379332249 hasConceptScore W4379332249C90924648 @default.
• W4379332249 hasIssue "16_suppl" @default.
• W4379332249 hasLocation W43793322491 @default.
• W4379332249 hasOpenAccess W4379332249 @default.
• W4379332249 hasPrimaryLocation W43793322491 @default.
• W4379332249 hasRelatedWork W1411054225 @default.
• W4379332249 hasRelatedWork W1979321249 @default.
• W4379332249 hasRelatedWork W2011500441 @default.
• W4379332249 hasRelatedWork W2474195589 @default.
• W4379332249 hasRelatedWork W2591863070 @default.
• W4379332249 hasRelatedWork W2596040508 @default.
• W4379332249 hasRelatedWork W2603773853 @default.
• W4379332249 hasRelatedWork W3191658268 @default.
• W4379332249 hasRelatedWork W3209233761 @default.
• W4379332249 hasRelatedWork W2118673085 @default.
• W4379332249 hasVolume "41" @default.
• W4379332249 isParatext "false" @default.
• W4379332249 isRetracted "false" @default.
• W4379332249 workType "article" @default.